| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the publication of a study titled "Keloid Excision With Primary Closure Combined With Superficial Radiation Therapy (SRT-100)" in the Annals of Plastic Surgery.
The single-site, retrospective study evaluated the clinical outcomes of combining surgical excision of keloids with primary wound closure followed by adjuvant Superficial Radiation Therapy (SRT) using Sensus Healthcare's SRT-100® system. The findings from follow-up visits involving 12 patients with 16 keloids indicate that no keloid recurrence was observed with most patients followed for more than six months, highlighting the efficacy of this treatment approach. This is Sensus Healthcare's first study in Asia and was conducted at Tri Service Military Hospital in Taiwan, which has been using the SRT-100® since 2023.
Posted In: SRTS
